Candel Therapeutics showcases cancer therapy candidates at IOVC

Candel Therapeutics (CADL) announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference, taking place October 27-30, 2024, in Rotterdam, the Netherlands. The presentations will showcase Candel’s advancements in innovative viral immunotherapies, including new data from the ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma, a presentation on a new multimodal immunotherapy candidate from the enLIGHTEN Discovery Platform, and a Company overview, focused on Candel’s broad clinical and preclinical pipeline. In detail: E. Antonio Chiocca, MD, PhD, Professor of Neurosurgery at Harvard Medical School, and recently appointed Executive Director of the Center for Tumors of the Nervous System and co-chair of the Executive Committee for Mass General Brigham Cancer Center, will deliver an oral presentation titled “Oncolytic immunoactivation clinical trial in rHGG: Preliminary safety and feasibility from longitudinal Injections.” The presentation will review safety and tolerability data from the multiple injection cohort of the ongoing phase 1b clinical trial of CAN-3110 in rHGG and will describe early clinical data and biomarker analysis from the first six patients enrolled in this cohort. The investigators observed ongoing improved survival compared to historical controls, with 3 out of 6 patients still alive after more than one year after initiation of experimental treatment with repeated CAN-3110 injections. The data also show discrepancies between imaging and histologic findings, suggesting radiologic pseudo-progression: there was a near absence of tumor cells alongside dense lymphocyte infiltrates in biopsies obtained after CAN-3110 administration, especially in patients with enhancement on post-treatment MRI scans. Qiuchen Guo, PhD, Discovery Scientist at Candel Therapeutics, will present a poster titled “A first-in-class multimodal immunotherapy for enhanced immune activation in the tumor microenvironment as a novel therapeutic strategy for solid tumors.” The presentation will focus on the latest asset from the enLIGHTEN Discovery Platform, a multimodal viral therapeutic candidate encoding IL-12 and IL-15. Data will include the ability of the asset to induce expansion and activation of natural killer and CD8+ T cell populations, resulting in significant tumor growth inhibition and regression in two different models. Francesca Barone, MD, PhD, CSO, will present a corporate overview of the company, titled “Off-the-shelf therapy, individualized anti-tumor response: Reprogramming the immune system by viral immunotherapy for the treatment of solid tumors.” This comprehensive review of Candel’s pipeline will include updates on clinical and preclinical programs with a focus on Candel’s lead experimental medicine, CAN-2409.